Ask AI
ProCE Banner Activity

CE / CME

Optimizing Management of HER2-Negative MBC: Experts Discuss the Now and Future Roles of TROP-2–Directed ADCs

Video

In this certified on-demand webcast, experts discuss TROP-2–directed antibody–drug conjugates in HER2-negative metastatic breast cancer (MBC), including evolving guideline implications and first-line use, sequencing strategies, toxicity management, and key ongoing clinical trials.

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

European Learners: 1.00 EBAC® CE Credit

Released: November 14, 2025

Expiration: May 13, 2026

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grant from Gilead Sciences, Inc.

Gilead Sciences, Inc.

Target Audience

This activity is intended for global oncologists and other healthcare professionals who care for patients worldwide with HER2-negative metastatic breast cancer.

Program Learning Goal

The goal of this activity is to improve learners’ knowledge, confidence, and competence in using TROP-2–directed antibody–drug conjugates for individualized management of patients with HER2-negative metastatic breast cancer. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Plan individualized treatment sequences incorporating TROP-2–directed ADCs to optimize clinical outcomes for patients with HER2-negative MBC

  • Implement evidence-based strategies for monitoring, prophylaxis, and management of adverse events associated with ADCs for patients with HER2-negative MBC

  • Evaluate the clinical implications of emerging evidence on novel approaches using ADCs for treatment of HER2-negative MBC, including in earlier lines of therapy and in combination with immunotherapy

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Javier Cortes, MD, PhD: consultant/advisor: Abbvie, AstraZeneca, Bioasis, Biocon, BioInvent, Biontech, Bliss Biopharmaceutical, Boehringer Ingelheim, BridgeBio, Circle Pharma, Clovis Oncology, Daiichi Sankyo, Delcath Systems, Ellipses, Expres2ion Biotechnologies, GEMoaB, Gilead, Hexagon Bio, Hibercell, Jazz, Leuko, Lilly, Menarini, Merck Sharp & Dohme, Reveal Genomics, Roche, Scorpion Therapeutics, Seattle Genetics, Zymeworks; honoraria: AstraZeneca, Daiichi Sankyo, Eisai, Gilead, Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Stemline, Zuellig; researcher (paid to institution): Ariad, AstraZeneca, Baxalta/Servier Affaires, Bayer Healthcare, Eisai, F. Hoffmann-La Roche, Guardant Health, Iqvia, Merck Sharp & Dohme, Pfizer, Piqur Therapeutics, Roche; individual publicly traded stock/stock options: Leuko; other financial or material support: AstraZeneca, Daiichi Sankyo, Eisai, Gilead, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Stemline; royalties or patent beneficiary: issued patent: Pharmaceutical Combinations of a PI3K Inhibitor and a Microtubule Destabilizing Agent (WO 2014/199294 A), licensed patent: HER2 as a Predictor of Response to Dual HER2 Blockade in the Absence of Cytotoxic Therapy (US 2019/0338368 A1).

Sara M. Tolaney, MD, MPH: consultant/advisor: Aadi Bio, Artios Pharma, Arvinas, AstraZeneca, Atkis Oncology, Avenzo, Bayer, BeOne, Blueprint Medicines, Bicycle Therapeutics, BioNTech, Boehringer Ingelheim, Bristol Myers Squibb/Systimmune, Celcuity, Circle Pharma, Cullinan Oncology, Daiichi Sankyo, eFFECTOR, Eisai, Genentech/Roche, Gilead, Hengrui USA, Jazz, Johnson & Johnson/Ambrx, Launch Therapeutics, Lilly, Menarini/Stemline, Merck, Mersana, Natera, Novartis, Olema, Pfizer/SeaGen, Reveal Genomics, Samsung Bioepis, Summit, Sumitovant, Tango, Tempus, Zuellig; researcher (paid to institution): AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Exelixis, Genentech/Roche, Gilead, Jazz, Lilly, Menarini/Stemline, Merck, NanoString, Novartis, OncoPep, Pfizer/SeaGen; other financial or material support: Arvians, AstraZeneca, Gilead, Jazz, Lilly, Pfizer, Roche.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, participants must follow these steps during the period from November 14, 2025, through May 13, 2026:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

EBAC® Accreditation 

A blue heart and yellow starsDescription automatically generated

Clinical Care Options, LLC is an EBAC® accredited provider since 2025.

This program is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) for 1 hour of effective education time.

EBAC® holds an agreement on mutual recognition of substantive equivalency with the US Accreditation Council for CME (ACCME) and the Royal College of Physicians and Surgeons of Canada, respectively.

Through an agreement between the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) and the American Medical Association, physicians may convert EBAC® External CME credits to AMA PRA Category 1 Credits™. Information on the

process to convert EBAC® credit to AMA credit can be found on the AMA website. Other health care professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 Credit™.

EBAC® is a member of the International Academy for CPD Accreditation (IACPDA) and a partner member of the International Association of Medical Regulatory Authorities (IAMRA).

A logo for a companyDescription automatically generated

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.